Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

17.77
+0.52003.01%
Pre-market: 18.150.3800+2.14%05:07 EDT
Volume:11.58M
Turnover:204.00M
Market Cap:20.38B
PE:-15.55
High:17.83
Open:17.58
Low:17.34
Close:17.25
Loading ...

Alvotech and Teva’s BLA filing for AVT06 accepted by FDA

TIPRANKS
·
18 Feb

BRIEF-Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application

Reuters
·
18 Feb

Alvotech Sa - Regulatory Approval Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - FDA Accepts for Review Bla for Alvotech's Biosimilar to Eylea

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval for Avt06 Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for Avt06, a Proposed Biosimilar to Eylea® (Aflibercept)

THOMSON REUTERS
·
18 Feb

Stanley Druckenmiller bought Tesla and these tech stocks last quarter

Dow Jones
·
18 Feb

Teva Announces Significant Holdings Disclosure

TIPRANKS
·
16 Feb

Top Executive Unloads Massive Teva Stock Stake, Raking in Millions!

TIPRANKS
·
15 Feb

Larry Robbins' Strategic Moves: Significant Reduction in Corteva Inc. by 3.62%

GuruFocus.com
·
15 Feb

Teva Reports Change in Officer Holdings

TIPRANKS
·
15 Feb

Why Axsome Therapeutics (AXSM) Is Advancing Today

Insider Monkey
·
12 Feb

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Zacks
·
11 Feb

Sector Update: Health Care Stocks Retreat Monday Afternoon

MT Newswires Live
·
11 Feb

Top Midday Gainers

MT Newswires Live
·
11 Feb

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Benzinga
·
11 Feb

Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation

Dow Jones
·
10 Feb

Axsome, Teva Settle Auvelity Patent Litigation

MT Newswires Live
·
10 Feb

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Business Wire
·
10 Feb

Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Business Wire
·
10 Feb